【2h】

Evaluation of Dosing Practices of Rivaroxaban andDabigatran

机译:利伐沙班和利伐沙班的给药实践评价达比加群

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

>Background: Anticoagulation is standard practice for the prevention and treatment of thromboembolic events. Two of the newer agents, rivaroxaban (Xarelto) and dabigatran (Pradaxa) are being utilized frequently in the inpatient and outpatient settings. Prescribers may not appreciate the need for dose reduction in the setting of renal insufficiency. >Objective: The objective of this study was to evaluate whether rivaroxaban and dabigatran were dosed according to recommendations in the package insert for patients with renal insufficiency. >Methods: Eligible patients were those >18 years of age who received rivaroxaban or dabigatran as an inpatient or had a prescription filled from the outpatient pharmacy. The use of the Cockcroft–Gault equation was utilized to calculate creatinine clearance to evaluate whether patients had appropriate manufacturer recommended dose reductions based on their renal function. >Results: There were very few patients (8 of 355, or 2.3%) who should have received a reduced dose when creatinine clearance was calculated utilizing actual body weight. In those patients with renal insufficiency, 3 of 6 (50.0%) patients receiving rivaroxaban and 1 of 2 (50%) patients receiving dabigatran were appropriately dosed. When ideal body weightwas substituted for creatinine clearance calculation, there were 15 patientsreceiving rivaroxaban and 10 patients receiving dabigatran who fell below thecreatinine clearance threshold for dose reduction. >Conclusions:Based on this evaluation, very few patients required a dose reduction due torenal insufficiency. It is important for clinicians to always monitor renalfunction when utilizing these medications to optimize the benefits of the neworal anticoagulants while limiting potential deleterious effects. Furthermore,it is necessary to ensure that actual body weight is being utilized forcreatinine clearance calculations with the new oral anticoagulants and not tobase dosing on estimated glomerular filtration rate or other calculatedcreatinine clearance as this could lead to inappropriate dose reductions.
机译:>背景:抗凝是预防和治疗血栓栓塞事件的标准做法。两种较新的药物,利伐沙班(Xarelto)和达比加群(Pradaxa)在住院和门诊患者中经常使用。处方者可能不了解在肾功能不全的情况下需要减少剂量。 >目的:该研究的目的是评估是否有根据肾功能不全患者的包装说明书中的推荐剂量利伐沙班和达比加群给药。 >方法:符合条件的患者是那些接受利伐沙班或达比加群住院治疗或由门诊药房开出处方的18岁以上的患者。使用Cockcroft-Gault方程计算肌酐清除率,以评估患者是否根据其肾功能适当降低了制造商建议的剂量。 >结果:根据实际体重计算肌酐清除率的患者很少(355名中的8名,占2.3%)。在那些肾功能不全的患者中,接受利伐沙班治疗的患者有6名患者中有3名(50.0%)和接受达比加群治疗的患者中有2名患者(50%)中有1名得到了适当剂量。理想体重时代替肌酐清除率计算,有15例患者接受利伐沙班治疗的患者和接受达比加群治疗的10例患者降低肌酐清除率的阈值。 >结论:根据此评估,由于以下原因,很少有患者需要降低剂量肾功能不全。对于临床医生而言,始终监测肾脏很重要利用这些药物来优化新药的功效口服抗凝剂,同时限制潜在的有害作用。此外,有必要确保将实际体重用于用新型口服抗凝剂进行肌酐清除率计算,而不是根据估计的肾小球滤过率或其他计算得出的剂量肌酐清除率,因为这可能导致不适当的剂量减少。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号